TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival

被引:39
作者
Wang, Y
Helland, Å
Holm, R
Skomedal, H
Abeler, VM
Danielsen, HE
Tropé, CG
Brresen-Dale, AL
Kristensen, GB [1 ]
机构
[1] Norwegian Radium Hosp, Dept Gynecol Oncol, N-0310 Oslo, Norway
[2] Norwegian Radium Hosp, Dept Genet, N-0310 Oslo, Norway
[3] Norwegian Radium Hosp, Dept Oncol, N-0310 Oslo, Norway
[4] Norwegian Radium Hosp, Dept Pathol, N-0310 Oslo, Norway
关键词
TP53 tumour-suppressor gene; TP53; mutation; TP53 protein accumulation; ovarian carcinoma; prognosis;
D O I
10.1038/sj.bjc.6601537
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We conducted the present study to evaluate the frequency and prognostic importance on long-term survival of TP53 mutations and TP53 protein accumulation in a cohort of 178 patients with early-stage ovarian carcinomas. TP53 mutations scored as aberrant temporal temperature gradient gel electrophoresis pattern from all exons were observed in 39.9% of the tumours. Full screening of exons 5-8, followed by sequencing, was successful in 135 cases, and 48 mutations altering the protein were detected in 39 cases (28.9%). TP53 mutations were slightly less common in the Federation of Gynecologists and Obstetricians stage IA than in IB/IC (P = 0.05). No significant correlations with histological type, grade of differentiation, DNA ploidy status or age at diagnosis were found. TP53 protein accumulation analysed by immunohistochemistry was found in 32.6% of all tumours, and was a poor predictor of TP53 mutations with 56.4% sensitivity, 77.1% specificity, 50% positive predictive value and 81.3% negative predictive value. Neither TP53 mutations nor TP53 protein accumulation influenced the prognosis significantly in this group of patients.
引用
收藏
页码:678 / 685
页数:8
相关论文
共 44 条
  • [1] Biological malignancy grading in early-stage ovarian carcinoma
    Auer, G
    Einhorn, N
    Nilsson, B
    Silfversward, C
    Sjovall, K
    [J]. ACTA ONCOLOGICA, 1996, 35 : 93 - 98
  • [2] Bjorge T, 1998, INT J CANCER, V75, P663, DOI 10.1002/(SICI)1097-0215(19980302)75:5<663::AID-IJC1>3.3.CO
  • [3] 2-4
  • [4] TP53 MUTATIONS AND BREAST-CANCER PROGNOSIS - PARTICULARLY POOR SURVIVAL RATES FOR CASES WITH MUTATIONS IN THE ZINC-BINDING DOMAINS
    BORRESEN, AL
    ANDERSEN, TI
    EYFJORD, JE
    CORNELIS, RS
    THORLACIUS, S
    BORG, A
    JOHANSSON, U
    THEILLET, C
    SCHERNECK, S
    HARTMAN, S
    CORNELISSE, CJ
    HOVIG, E
    DEVILEE, P
    [J]. GENES CHROMOSOMES & CANCER, 1995, 14 (01) : 71 - 75
  • [5] Borresen Anne-Lise, 1996, P267
  • [6] Borresen-Dale AL, 1998, CLIN CANCER RES, V4, P203
  • [7] TP53 and breast cancer
    Borresen-Dale, AL
    [J]. HUMAN MUTATION, 2003, 21 (03) : 292 - 300
  • [8] p53 mutations and microsatellite instability in ovarian cancer: Yin and Yang
    Buller, RE
    Shahin, MS
    Holmes, RW
    Hatterman, M
    Kirby, PA
    Sood, AK
    [J]. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 2001, 184 (05) : 891 - 902
  • [9] p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: A molecular and immunohistochemical study
    Buttitta, F
    Marchetti, A
    Gadducci, A
    Pellegrini, S
    Morganti, M
    Carnicelli, V
    Cosio, S
    Gagetti, O
    Genazzani, AR
    Bevilacqua, G
    [J]. BRITISH JOURNAL OF CANCER, 1997, 75 (02) : 230 - 235
  • [10] DEMBO AJ, 1990, OBSTET GYNECOL, V75, P263